634 related articles for article (PubMed ID: 31209565)
1. One-year evaluation of clinical and immunological efficacy and safety of sublingual versus subcutaneous allergen immunotherapy in allergic conjunctivitis.
Sayed KM; Kamel AG; Ali AH
Graefes Arch Clin Exp Ophthalmol; 2019 Sep; 257(9):1989-1996. PubMed ID: 31209565
[TBL] [Abstract][Full Text] [Related]
2. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
3. Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma.
Hesse L; Petersen AH; Nawijn MC
Methods Mol Biol; 2021; 2223():295-335. PubMed ID: 33226602
[TBL] [Abstract][Full Text] [Related]
4. Allergen Immunotherapy: The Evidence Supporting the Efficacy and Safety of Subcutaneous Immunotherapy and Sublingual Forms of Immunotherapy for Allergic Rhinitis/Conjunctivitis and Asthma.
Creticos PS; Gunaydin FE; Nolte H; Damask C; Durham SR
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1415-1427. PubMed ID: 38685477
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Sublingual Immunotherapy in the Treatment of HDM-Induced Nasobronchial Allergies: A 3-Year Randomized Case-Control Study From Kashmir.
Baba SM; Rasool R; Gull A; Qureshi TA; Beigh AH; Qadri Q; Shah ZA
Front Immunol; 2021; 12():723814. PubMed ID: 34721385
[TBL] [Abstract][Full Text] [Related]
6. Optimum treatment strategies for polyallergic patients - analysis of a large observational trial.
Shah-Hosseini K; Mioc K; Hadler M; Karagiannis E; Mösges R
Curr Med Res Opin; 2015 Dec; 31(12):2249-59. PubMed ID: 26366617
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
Hesse L; Nawijn MC
Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
[TBL] [Abstract][Full Text] [Related]
8. Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis.
Wang ZX; Shi H
J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):407-411. PubMed ID: 28585143
[TBL] [Abstract][Full Text] [Related]
9. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
10. Does evidence support the use of cat allergen immunotherapy?
Dhami S; Agarwal A
Curr Opin Allergy Clin Immunol; 2018 Aug; 18(4):350-355. PubMed ID: 29870462
[TBL] [Abstract][Full Text] [Related]
11. Selection of patients for sublingual versus subcutaneous immunotherapy.
Larenas Linnemann DE; Blaiss MS
Immunotherapy; 2014; 6(7):871-84. PubMed ID: 25290418
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
[TBL] [Abstract][Full Text] [Related]
14. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
15. Two year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing subcutaneous and sublingual immunotherapy.
Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
Asian Pac J Allergy Immunol; 2013 Sep; 31(3):233-41. PubMed ID: 24053706
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases.
Li P; Li Q; Huang Z; Chen W; Lu Y; Tian M
Int Forum Allergy Rhinol; 2014 Oct; 4(10):796-801. PubMed ID: 25145986
[TBL] [Abstract][Full Text] [Related]
17. Compliance in subcutaneous and sublingual allergen immunotherapy: A nationwide study.
Borg M; Løkke A; Hilberg O
Respir Med; 2020; 170():106039. PubMed ID: 32843170
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous allergen-specific immunotherapy versus topical treatment in vernal keratoconjunctivitis.
Mahdy RA; Nada WM; Marei AA
Cornea; 2012 May; 31(5):525-8. PubMed ID: 22314814
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
[TBL] [Abstract][Full Text] [Related]
20. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
Ellis AK; Tenn MW; Steacy LM; Adams DE; Day AG; Walker TJ; Nolte H
Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
